拉斐尔控股股价走低。该公司宣布，其子公司Cyclo Therapeutics的为期96周的关键3期TransportNPC研究评估静脉注射Trappsol Cyclo治疗C1型尼曼-皮克病的潜在可能性，将继续根据独立数据监测委员会在预先指定的48周中期分析中对安全性和有效性数据的审查。

Rafael Holdings shares are trading lower. The company announced its subsidiary Cyclo Therapeutics' 96-week pivotal phase 3 TransportNPC study evaluating intravenous Trappsol Cyclo for the potential treatment of Niemann-Pick Disease Type C1 will continue based on the independent Data Monitoring Committee review of safety and efficacy data at the prespecified 48-week interim analysis.